#Sweden #Capital Markets #Stockholm #Sobi

Sobi's Capital Markets Day: A Look Ahead

Swedish Orphan Biovitrum AB (Sobi), a leader in biopharmaceuticals, is set to host its much-anticipated Capital Markets Day (CMD) on February 18, 2026. This year's event takes place in Stockholm, Sweden, beginning at 13:00 CET, and it presents a unique opportunity for investors, analysts, and stakeholders to gain critical insights into the company's future strategies and innovations.

Event Overview

The CMD will feature presentations from Sobi's CEO, Guido Oelkers, along with various members of the management team. They will delve into updates concerning Sobi’s strategic vision, and outline advancements in their therapeutic areas. The agenda promises a comprehensive overview, including updates on Sobi’s innovative pipeline and strategic ambitions looking towards 2030.

The sessions will be designed to inform participants about recent advancements and future directions within the company, including deep dives into specific diseases that Sobi addresses. The event will conclude around 16:00 CET, allowing ample time for attendees to engage during a Q&A session where they can address their queries directly to the Sobi leadership team.

Key Presentations

Key highlights of the CMD will include:

• - Guido Oelkers - CEO of Sobi, presenting the Ambition 2030 strategy.
• - Lydia Abad-Franch - Chief Medical Officer, discussing Sobi's pipeline and innovation efforts.
• - Robert Keenan - CMO of Arthrosi, offering a deep dive into the impact of severe gout on patients’ lives.
• - Duane Barnes and Team - facilitating a roundtable addressing regional strategic insights.
• - Professor Klaus Parhofer - focusing on the silent risks of sHTG (severe hypertriglyceridemia).
• - Professor Evangelos Giamarellos - highlighting precision medicine in sepsis, a key area for ongoing research and innovation.
• - Henrik Stenqvist - CFO, presenting on delivering shareholder value.

Why You Should Attend

This CMD serves as a critical platform for Sobi to communicate its strategic objectives and gather feedback from its investor community. Stakeholders will gain access to essential information that can shape their investment strategies moving forward. Additionally, the opportunity to ask questions directly to the executives is invaluable for anyone looking to understand Sobi's role and potential within the biopharmaceutical market.

For those unable to attend in person, a live webcast will be offered, allowing remote participants to engage with the insights being shared. It is recommended that attendees pre-register for the event to ensure their spot at this pivotal gathering.

About Sobi

Sobi is a global biopharma company dedicated to unlocking groundbreaking innovations aimed at improving the lives of those living with rare diseases. With a workforce of approximately 1,900 employees spread across Europe, North America, the Middle East, Asia, and Australia, Sobi ended 2025 with substantial revenue of SEK 28 billion. The company's advancements, strategies, and collaborative efforts highlight its commitment to transforming healthcare trajectories.

Participants interested in the CMD can find more information, including registration details, by visiting Sobi's official website. As Sobi navigates its journey in the competitive biopharmaceutical field, this day promises rich discussions and forward-thinking insights likely to influence the market significantly.

We look forward to witnessing Sobi's continual evolution and the advances it will bring to patient care in the rare diseases sector.